Genelux
GNLX | NASDAQ
$1.92
+$0.05 (+2.95%)
At close: Nov 16, 2026, 4:00 PM ET
$1.80
-$0.12 (-6.16%)
After-hours:
Nov 16, 2026, 7:20 PM ET
+2.95%
(1D)No price chart data available for 1D timeframe.
Rating
34.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #659/1021 (Top 65%)
Key Statistics
Market Data
Market Cap $86.87M
1D Range
1.86 2.02
52W Range
1.82 5.59
Valuation (TTM)
PE -2.16
PB 5.39
EV/EBITDA -2.07
Valuation (NTM)
Forward PE N/A
Forward PEG 0.56
Price Target $16.00
Cash Flow
FCF Yield -33.0%
SBC Adj. FCF Yield -41.2%
SBC Impact -24.7%
Margins
Gross Margin -1762.5%
Operating Margin -445200.0%
FCF Margin -358537.5%
Growth (CAGR)
Revenue 3Y | 5Y -91.1% |
-49.9%
Dil EPS 3Y | 5Y 3.9% |
-11.4%
FCF 3Y | 5Y -13.1% |
-35.8%
Returns
ROA -129.0%
ROE -195.4%
ROIC -192.2%
Financial Health
Net Cash
$16.25M
Current Ratio 2.39
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor ma...
Sector Healthcare
Industry Biotechnology
Employees 26
IPO Date Jan 26, 2023
Website www.genelux.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$16.00
Upside
+733.33%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove GNLX